Format

Send to

Choose Destination
Lancet. 2014 Oct 4;384(9950):1302-10. doi: 10.1016/S0140-6736(14)60834-5.

Fertility preservation in women with cancer.

Author information

1
Centre for Reproductive Medicine, UZ Brussel, Brussels, Belgium. Electronic address: mdevos@uzbrussel.be.
2
Laboratory of Clinical Chemistry and Radioimmunology, UZ Brussel, Brussels, Belgium.
3
Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Erratum in

  • Lancet. 2015 Mar 7;385(9971):856.

Abstract

Enhanced long-term survival rates of young women with cancer and advances in reproductive medicine and cryobiology have culminated in an increased interest in fertility preservation methods in girls and young women with cancer. Present data suggest that young patients with cancer should be referred for fertility preservation counselling quickly to help with their coping process. Although the clinical application of novel developments, including oocyte vitrification and oocyte maturation in vitro, has resulted in reasonable success rates in assisted reproduction programmes, experience with these techniques in the setting of fertility preservation is in its infancy. It is hoped that these and other approaches, some of which are still regarded as experimental (eg, ovarian tissue cryopreservation, pharmacological protection against gonadotoxic agents, in-vitro follicle growth, and follicle transplantation) will be optimised and become established within the next decade. Unravelling the complex mechanisms of activation and suppression of follicle growth will not only expand the care of thousands of women diagnosed with cancer, but also inform the care of millions of women confronted with reduced reproductive fitness because of ageing.

PMID:
25283571
PMCID:
PMC4270060
DOI:
10.1016/S0140-6736(14)60834-5
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center